Covington, Freshfields Advise On $6.7B Merck Oncology Deal
By Al Barbarino · March 25, 2026, 12:10 PM EDT
Merck & Co. said Wednesday it will acquire clinical-stage oncology company Terns Pharmaceuticals Inc. for $53 per share in cash, giving the deal an equity value of $6.7 billion....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login